16 Results
Sort By:
Published on April 8, 2024
Enhertu (AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan) has become the first tumor-agnostic, FDA-approved, HER2-directed therapy. It is approved for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors. Enhertu is an antibody drug conjugate (ADC) that consists of a HER2 monoclonal antibody attached to a number of topoisomerase…
Published on January 30, 2024
One of the most competitive fields in pharma today involves antibody drug conjugates (ADCs), a market estimated to be worth almost $20B already. This week the FDA accepted the supplemental Biologics License Application (sBLA) for ADC Enhertu (fam-trastuzumab deruxtecan-nxki) and granted it Priority Review. Enhertu is a HER2-directed ADC being…
Published on August 8, 2022
On Friday, the U.S. Food and Drug Administration (FDA) approved trastuzumab-deruxtecan—sold under the brand name Enhertu—for the treatment of patients with unresectable or metastatic HER2-low breast cancer. Administered through IV infusion, the drug is the first approved therapy for patients with the newly identified HER2-low breast cancer subtype. The expanded…
Published on June 6, 2022
AstraZeneca has established that targeting HER-2 low breast cancer works, and very well, by presenting striking Phase III results at the American Society of Clinical Oncology (ASCO) this week. Enhertu (trastuzumab deruxtecan) demonstrated a 49% reduction in the risk of disease progression or death versus chemotherapy in patients with HER2-low metastatic breast…
Published on February 5, 2024
A genetic signature for HER2-low tumors has been found that may solve a problem for those seeking wider use of drugs targeting such cancers, particularly antibody drug congugate (ADC) Enhertu (trastuzumab-deruxtecan/T-DXd). ADCs carry a payload that helps them be especially effective. Their 20-gene signature, the team says, shows promise in…
Published on December 19, 2023
Two new deals around antibody drug conjugates (ADCs) were just struck. Pfizer will develop and commercialize Nona Biosciences’ MSLN-targeted ADC HBM9033 in a deal worth potentially $1B+. Meanwhile, Biocytogen Pharmaceuticals announced an antibody evaluation, option, and license agreement with Ona Therapeutics. The deal includes an option to exclusively license selected…
Published on December 12, 2023
Bristol Myers Squibb (BMS) will co-develop SystImmune’s BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC) in the United States. The deal is worth potentially more than $8B. “Recent BL-B01D1 trials have shown broad potential across different solid tumors as well as a manageable safety profile,” said Yi Zhu, CEO…
Published on December 4, 2023
AstraZeneca is the latest big pharma to partner with a company using artificial intelligence (AI) to help design drugs in a collaboration with U.S.-based Absci to design a cancer fighting antibody drug. According to the Financial Times, who announced the deal over the weekend, the partnership is worth up to…
Published on November 8, 2023
Bristol Myers Squibb is acquiring Orum Therapeutics’ ORM-6151 program for $100M upfront and total deal value of $180M. In a twist on antibody-drug conjugates (ADCs), Orum is pioneering Dual-Precision Targeted Protein Degradation (TPD²) and Targeted Protein Stabilization (TPS²). ORM-6151 is a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader that has received the…
Published on October 20, 2023
In a $4B upfront deal, Merck is acquiring three of Daiichi Sankyo’s antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd). The two companies will jointly develop and commercialize these drugs worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Total potential consideration…
Published on October 12, 2023
China-headquartered MediLink Therapeutics has entered into a deal with BioNTech for development of a next-generation antibody-drug conjugate candidate (ADC) against Human Epidermal Growth Factor Receptor 3 (HER3). With an upfront payment of $70M and plenty of additional development, regulatory, and commercial milestone payments, the deal could be worth over $1 billion.…
Published on May 9, 2023
In the latest high profile antibody drug conjugate (ADC) deal, this week Hangzhou-based Bliss Biopharmaceutical (BlissBio) announced a clinical trial collaboration agreement with Eisai for its lead ADC BB-1701, which is in Phase I/II in China and the U.S. BB-1701 has an eribulin-payload directed against Human Epidermal Growth Factor Receptor…
Published on September 29, 2022
Pheon Therapeutics launched this week following the closing of a $68 million Series A financing in March 2022. The investment will allow Pheon to advance its lead antibody-drug-conjugate (ADC) program to clinical proof-of-concept and establish a pipeline of novel ADCs for hard-to-treat cancers. The financing was led by Brandon Capital,…
Published on August 16, 2022
By Scott Tomlins, MD, PhD, Co-Founder & Chief Medical Officer, Strata Oncology Sponsored content brought to you by ADCs are part of the expression-based therapy revolution in cancer treatment Oncology is seeing accelerated development of new expression-based therapy classes with the potential to deliver unprecedented improvements in patient outcomes.…
Published on September 21, 2021
Over the last week, the world of cancer research, diagnostics and therapeutics has been congregating on the European Society of Medical Oncology (ESMO) website to view a wide variety of cutting-edge research presentations at the organization’s annual conference. The biggest congress in Europe with a focus on cancer research, the…